Cancer Research UK logo.
SearchDonate
  • Search

A trial of vandetanib and selumetinib for solid tumours including non small cell lung cancer (VanSel-1)

Overview

Cancer types:

All cancer types, Lung cancer, Non small cell lung cancer (NSCLC)

Status:

Results

Phase:

Phase 1

Details

This trial looked at vandetanib and selumetinib for people who have , including non small cell lung cancer. A solid tumour is any cancer apart from leukaemia or lymphoma.

The trial was supported by Cancer Research UK. It was open for people to join between 2011 and 2017. The team reported the results in 2021.

Recruitment start: 16 December 2011

Recruitment end: 13 October 2017

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Denis Talbot

Supported by

AstraZeneca

Cancer Research UK (Centre for Drug Development) - trial sponsor, regulatory@cancer.org.uk

Experimental Cancer Medicine Centre (ECMC)

NIHR Clinical Research Network: Cancer

Other information

This is Cancer Research UK trial number CRUKD/11/001.

There is more information about this trial (NCT01586624) on the clinicaltrials.gov website:

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

Last reviewed: 02 Aug 2022

CRUK internal database number: 6787

Help and support